Asian Currencies Trade Flat as Dollar Retreats After Fed Decision 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
